Safety And Efficacy Study Of Ziprasidone In Pediatric Psychotic Illness

• Status: Completed
• Trial end date: 2007-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research is to determine if Ziprasidone is safe and effective for use in children and adolescents with a psychotic illness, and to determine of Ziprasidone treatment leads to weight changes in children.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical College of Wisconsin
• Treatments: Ziprasidone

Criteria

Inclusion Criteria:

• Diagnosis of Schizophrenia, Schizophreniform DO, Schizoaffective DO or Psychotic Disorder NOS

• Male/female, ages 7.0-17 years old

• Normal intelligence, ability to provide assent and consent

• Not currently receiving adequate treatment

Exclusion Criteria:

• Known hypersensitivity to ziprasidone (past failed trial)

• History of QTc prolongation

• Recent myocardial infarction

• Uncompensated heart failure

• Currently treated with other QTc prolonging medications

• Unstable medical illness

• If on diuretics, monitor regularly for hypokalemia